An unexpected N-terminal loop in PD-1 dominates binding by nivolumab

Nature Communications

Volumn 8, Issue , 2017, Pages

  Tan, Shuguang ^a   Zhang, Hao ^a,b   Chai, Yan ^a   Song, Hao ^c   Tong, Zhou ^a   Wang, Qihui ^a   Qi, Jianxun ^a   Wong, Gary ^a   Zhu, Xiaodong ^d   Liu, William J ^e   Gao, Shan ^f   Wang, Zhongfu ^g   Shi, Yi ^a   Yang, Fuquan ^h   Gao, George F ^a,c,e   Yan, Jinghua ^a,b  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b ANHUI UNIVERSITY   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d Beijing Combio Co Ltd   (China)

^e CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^f SUZHOU INSTITUTE OF BIOMEDICAL ENGINEERING AND TECHNOLOGY   (China)

^g NORTHWEST UNIVERSITY   (China)

^h INSTITUTE OF BIOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROTEIN BINDING;

ANTIBODY; CANCER; CHEMICAL ALTERATION; CHEMICAL BINDING; GENE; GENE EXPRESSION; IMMUNE RESPONSE; INHIBITION;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER IMMUNOTHERAPY; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG TARGETING; IMMUNOGLOBULIN DOMAIN; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN GLYCOSYLATION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DESIGN; GLYCOSYLATION; HUMAN; IMMUNOTHERAPY; METABOLISM; NEOPLASM; PROCEDURES; PROTEIN DOMAIN; X RAY CRYSTALLOGRAPHY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; GLYCOSYLATION; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN BINDING; PROTEIN DOMAINS;

EID: 85011632749     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms14369     Document Type: Article

References (55)

1. Couzin-Frankel, J. Breakthrough of the year 2013. Cancer immunotherapy. Science 342, 1432-1433 (2013).
2. Gao, G. F. et al. Crystal structure of the complex between human CD8alpha(alpha), HLA-A2. Nature 387, 630-634 (1997).
3. Gao, G. F. , Jakobsen, B. K. Molecular interactions of coreceptor CD8, MHC class I: the molecular basis for functional coordination with the T-cell receptor. Immunol. Today 21, 630-636 (2000).
4. Collins, A. V. et al. The interaction properties of costimulatory molecules revisited. Immunity 17, 201-210 (2002).
5. Bretscher, P. , Cohn, M. A theory of self-nonself discrimination. Science 169, 1042-1049 (1970).
6. Lafferty, K. J. , Cunningham, A. J. A new analysis of allogeneic interactions. Aust. J. Exp. Biol. Med. Sci. 53, 27-42 (1975).
7. Cunningham, A. J. , Lafferty, K. J. A simple conservative explanation of the H-2 restriction of interactions between lymphocytes. Scand. J. Immunol. 6, 1-6 (1977).
8. Tan, S. , Gao, G. F. New hope for cancer treatment: cancer immunotherapy. Chin. Sci. Bull. 60, 3155-3157 (in Chinese) (2015).
9. Callahan, M. K. , Postow, M. A. , Wolchok, J. D. Targeting T cell co-receptors for cancer therapy. Immunity 44, 1069-1078 (2016).
10. Salomon, B. , Bluestone, J. A. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity, transplantation. Annu. Rev. Immunol, 19, 225-252 (2001).
11. Ishida, Y. , Agata, Y. , Shibahara, K. , Honjo, T. Induced expression of Pd-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell-death. EMBO J. 11, 3887-3895 (1992).
12. Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027-1034 (2000).
13. Latchman, Y. W. C. et al. PD-L2 is a second ligand for PD-1, inhibits T cell activation. Nat. Immunol. 2, 261-268 (2001).
14. Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system, tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99, 12293-12297 (2002).
15. Blackburn, S. D. et al. Coregulation of CD8(\+) T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10, 29-37 (2009).
16. Curiel, T. J. et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9, 562-567 (2003).
17. Wang, H. Y. et al. Tumor-specific human CD4\+ regulatory T cells, their ligands: implications for immunotherapy. Immunity 20, 107-118 (2004).
18. Francisco, L. M. et al. PD-L1 regulates the development, maintenance, , function of induced regulatory T cells. J. Exp. Med. 206, 3015-3029 (2009).
19. Chen, L. , Han, X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, , future. J. Clin. Invest. 125, 3384-3391 (2015).
20. Li, Y. et al. A mini-review for cancer immunotherapy: molecular understanding of PD-1/PD-L1 pathway & translational blockade of immune checkpoints. Int. J. Mol Sci. 17, 1151-1172 (2016).
21. Zou, W. , Wolchok, J. D. , Chen, L. PD-L1 (B7-H1), PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, , combinations. Sci. Transl. Med. 8, 328rv4 (2016).
22. Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, , immunologic correlates. J. Clin. Oncol. 28, 3167-3175 (2010).
23. Topalian, S. L. et al. Safety, activity, , immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
24. Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803-1813 (2015).
25. Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320-330 (2015).
26. Liu, K. et al. Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy. Cell. Res. 27, 151-153 (2016).
27. Na, Z. et al. Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. Cell. Res. 27, 147-150 (2016).
28. Tan, S. et al. Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein Cell 7, 866-877 (2016).
29. Tan, S. , Zhang, C. W-H. , Gao, G. F. Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy. Signal. Transd. Targeted Ther. 1, e16029 (2016).
30. Zak, K. M. et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget 7, 30323-30335 (2016).
31. Munkley, J. , Mills, I. G. , Elliott, D. J. The role of glycans in the development, progression of prostate cancer. Nat. Rev. Urol. 13, 324-333 (2016).
32. Xu, C. , Ng, D. T. Glycosylation-directed quality control of protein folding. Nat. Rev. Mol. Cell Biol. 16, 742-752 (2015).
33. Hakomori, S. , Kannagi, R. Glycosphingolipids as tumor-associated, differentiation Markers. J. Natl. Cancer Inst. 71, 231-251 (1983).
34. Kudelka, M. R. , Ju, T. , Heimburg-Molinaro, J. , Cummings, R. D. Chapter three-imple sugars to complex disease-mucin-type Oglycans in cancer. Adv. Cancer Res. 126, 53-135 (2015).
35. Pinho, S. S. , Reis, C. A. Glycosylation in cancer: mechanisms, clinical implications. Nat. Rev. Cancer 15, 540-555 (2015).
36. Kleffel, S. et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell 162, 1242-1256 (2015).
37. Lazar-Molnar, E. et al. Crystal structure of the complex between programmed death-1 (PD-1), its ligand PD-L2. Proc. Natl Acad. Sci. USA 105, 10483-10488 (2008).
38. Lin, D. Y. et al. The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies, T cell receptors. Proc. Natl Acad. Sci. USA 105, 3011-3016 (2008).
39. Zak, K. M. et al. Structure of the complex of human programmed death 1, PD-1, , its ligand PD-L1. Structure 23, 2341-2348 (2015).
40. Higel, F. , Seidl, A. , Sorgel, F. , Friess, W. N-glycosylation heterogeneity, the influence on structure, function, pharmacokinetics of monoclonal antibodies, Fc fusion proteins. Eur. J. Pharm. Biopharm. 100, 94-100 (2016).
41. Jiang, N. et al. Effects of anchor structure, glycosylation of fcgamma receptor III on ligand binding affinity. Mol. Biol. Cell 27, 3449-3458 (2016).
42. Postow, M. A. et al. Nivolumab, ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006-2017 (2015).
43. Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521-2532 (2015).
44. Bang, Y.-J. et al. Relationship between PD-L1 expression, clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. J. Clin. Oncol. 33, Suppl 3; abstr 4001 (2015).
45. Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018-2028 (2015).
46. O'Donnell, Peter H. et al. Pembrolizumab (Pembro; MK-3475) for advanced urothelial cancer: results of a phase IB study. J. Clin. Oncol. 33, Suppl 7; abstr 296 (2015).
47. Song, H. et al. An open receptor-binding cavity of hemagglutinin-esterasefusion glycoprotein from newly-identified influenza D virus: basis for its broad cell tropism. PLoS Pathog. 12, e1005411 (2016).
48. Zhang, W. et al. Crystal structure of the swine-origin A (H1N1)-2009 influenza A virus hemagglutinin (HA) reveals similar antigenicity to that of the 1918 pandemic virus. Protein Cell 1, 459-467 (2010).
49. Chen, Y. et al. A dimeric structure of PD-L1: functional units or evolutionary relics? Protein Cell 1, 153-160 (2010).
50. Otwinowski, Z. , Minor, W. Processing of X-ray diffraction data. Methods Enzymol. 276, 307-326 (1997).
51. Read, R. J. Pushing the boundaries of molecular replacement with maximumlikelihood. Acta. Crystallogr. D. Biol. Crystallogr. 57, 1373-1382 (2001).
52. Collaborative Computational Project, N. The CCP4 suite: programs forprotein crystallography. Acta. Crystallogr. D. Biol. Crystallogr. 50, 760-763 (1994).
53. Emsley, P. , Cowtan, K. Coot: model-building tools for molecular graphics. Acta. Crystallogr. D. Biol. Crystallogr. 60, 2126-2132 (2004).
54. Adams, P. D. et al. PHENIX: a comprehensive Python-based system formacromolecular structure solution. Acta. Crystallogr. D. Biol. Crystallogr. 66, 213-221 (2010).
55. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta. Crystallogr. D. Biol. Crystallogr. 66, 12-21 (2010).